Jamie L. Reynoso - Oct 3, 2025 Form 4 Insider Report for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Role
CEO, Medicare Advantage
Signature
/s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso
Stock symbol
CLOV
Transactions as of
Oct 3, 2025
Transactions value $
-$27,880
Form type
4
Date filed
10/7/2025, 04:37 PM
Previous filing
Sep 19, 2025
Next filing
Oct 17, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Reynoso Jamie L. CEO, Medicare Advantage C/O CLOVER HEALTH INVESTMENTS, CORP., NOT APPLICABLE, WILMINGTON /s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso 2025-10-07 0001839066

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLOV Class A Common Stock Tax liability -$22.5K -8.71K -0.29% $2.59 3.05M Oct 3, 2025 Direct F1
transaction CLOV Class A Common Stock Sale -$5.33K -2.01K -0.07% $2.65 3.04M Oct 7, 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations due to the vesting on October 3, 2025, of 6.25% of the restricted stock units ("RSUs") granted to the Reporting Person on January 3, 2023, and originally reported on a Form 4 filed on January 5, 2023. The remaining RSUs will vest in equal quarterly installments, with the final vesting occurring on January 3, 2027, in each case subject to the continued service of the Reporting Person on each such vesting date.
F2 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025. These shares were sold at a price of $2.65.